Franses, Joseph W.
Philipp, Julia
Missios, Pavlos
Bhan, Irun http://orcid.org/0000-0002-2163-0488
Liu, Ann http://orcid.org/0000-0002-0908-3506
Yashaswini, Chittampalli
Tai, Eric
Zhu, Huili
Ligorio, Matteo
Nicholson, Benjamin
Tassoni, Elizabeth M.
Desai, Niyati
Kulkarni, Anupriya S.
Szabolcs, Annamaria http://orcid.org/0000-0003-4951-9914
Hong, Theodore S.
Liss, Andrew S. http://orcid.org/0000-0002-4040-9172
Fernandez-del Castillo, Carlos
Ryan, David P.
Maheswaran, Shyamala
Haber, Daniel A.
Daley, George Q.
Ting, David T. http://orcid.org/0000-0002-3261-2322
Funding for this research was provided by:
Howard Hughes Medical Institute
Burroughs Wellcome Fund
Foundation for the National Institutes of Health (R01CA235412)
Article History
Received: 28 October 2019
Accepted: 11 June 2020
First Online: 3 July 2020
Competing interests
: D.T.T. has received consulting fees from Merrimack Pharmaceuticals, Ventana Roche, Foundation Medicine, Inc., and EMD Millipore Sigma, which are not related to this work. D.T.T. is a founder and has equity in TellBio, Inc. that is related to circulating tumor cells and with intellectual property that is to be licensed to the company. D.T.T. is a founder and has equity in ROME therapeutics and PanTher Therapeutics, which is not related to this work. D.T.T. receives research support from ACD-Biotechne, PureTech Health, and Ribon Therapeutics, which were not related to this work. Dr. Ting’s interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies.